To The Moon

Yesterday, the U.S. biotech sector showed strong momentum, with the $纳斯达克生物技术指数(NBI)$ rising 2.64% in a single day. From a structural perspective, gains were broadly distributed across small- and mid-cap innovative drug companies, with $Sarepta Therapeutics(SRPT)$ surging nearly 35% and multiple names such as $Arrowhead Research Corporation(ARWR)$ and $Arvinas Holding Company LLC(ARVN)$ rising more than 5%, indicating a clear breadth-driven rally.

From a one-day performance perspective, biotech-related ETFs moved higher across the board, with stronger gains in innovative and high-beta segments. $SPDR S&P Biotech ETF(XBI)$ rose 3.66%, $ALPS Medical Breakthroughs ETF(SBIO)$ gained 3.81%, and $First Trust NYSE Arca Biotechnology Index Fund(FBT)$ advanced 3.56%, all of which are more exposed to small-cap biotech companies, reflecting concentrated capital inflows into higher-beta names. $生物科技指数ETF-iShares Nasdaq(IBB)$ rose 2.54% and $INVESCO BIOTECHNOLOGY & GENOME ETF(PBE)$ gained 2.05%, representing a more balanced recovery across large-cap and thematic biotech exposure. Leveraged product $三倍做多标普生物-Direxion(LABU)$ jumped 11.02%, significantly amplifying sector moves. In contrast, more defensive healthcare ETFs such as $健康照护类股ETF-SPDR(XLV)$ rose only 1.00%, while $全球医疗业ETF-iShares(IXJ)$ gained 1.12%, highlighting a clear divergence in market positioning.

One notable shift in the market has been the renewed activity of large pharmaceutical companies in M&A. On March 25, Merck announced an approximately $6.7 billion all-cash acquisition of Terns Pharmaceuticals. Beyond the deal itself, the pricing drew greater attention — a premium of around 6% led to discussions about the possibility of competing bids, providing a new reference point for the valuation of innovative drug assets.

Against this backdrop, capital allocation has tilted. Small- and mid-cap biotech companies, characterized by pipeline optionality and higher likelihood of becoming acquisition targets, have increasingly drawn investor interest. Although these companies carry relatively low weights in major indices, their large number means that concentrated buying can drive broad-based gains across constituents.

During the same period, multiple streams of information also emerged within the sector. On the clinical side, several companies released key updates — for example, Ionis and Biogen advanced projects related to spinal muscular atrophy, while Arvinas reported early-stage data in neurodegenerative disease pipelines. On the financing and corporate side, companies such as Apogee disclosed funding or operational updates, contributing to notable stock movements.

On the regulatory front, Denali’s therapy for Hunter syndrome reached a key FDA milestone, with market expectations for approval remaining relatively high. In addition, multiple oncology and immunology programs reported Phase 2 or Phase 3 data at recent conferences. While these developments are not uniform, their concentration within a short time frame has increased overall sector activity and supported continued capital inflows.

Looking at a longer time horizon, the NBI index peaked in 2021 and subsequently underwent an extended correction, with the sector remaining under pressure through 2022 and 2023 before gradually recovering in 2024. At current levels, the index has rebounded but has yet to establish a sustained new high:

Market attention may gradually shift from the sector as a whole toward individual companies. On one hand, progress in pipeline development may receive greater scrutiny; on the other hand, assets with potential M&A appeal may continue to attract discussion.

Related ETF Overview:

In terms of scale, $健康照护类股ETF-SPDR(XLV)$ has total assets of approximately $38.806 billion and an expense ratio of just 0.03%, making it one of the largest and most liquid healthcare ETFs, with a more defensive tilt toward large pharmaceutical and healthcare service companies. $生物科技指数ETF-iShares Nasdaq(IBB)$ , with assets of about $8.003 billion and an expense ratio of 0.44%, is the largest biotech-focused ETF, concentrated in industry leaders and suitable for more stable exposure.

For mid-cap and balanced exposure, $SPDR S&P Biotech ETF(XBI)$ manages around $7.710 billion with a 0.35% expense ratio and uses an equal-weighted structure, providing greater exposure to smaller companies and higher upside potential. $First Trust NYSE Arca Biotechnology Index Fund(FBT)$ , with approximately $2.244 billion in assets and a 0.40% expense ratio, also follows an equal-weight approach, offering diversified exposure and stronger performance during sector rallies.

In more specialized and higher-volatility segments, $INVESCO BIOTECHNOLOGY & GENOME ETF(PBE)$ manages about $0.243 billion with a 0.50% expense ratio, focusing on genetic engineering and biotechnology themes, while $ALPS Medical Breakthroughs ETF(SBIO)$ , with $0.126 billion in assets and a 0.50% fee, targets small-cap biotech companies with higher risk and return potential.

Among leveraged products, $三倍做多标普生物-Direxion(LABU)$ manages approximately $0.530 billion with a 0.75% expense ratio and provides 3x daily exposure to the biotech index, making it more suitable for short-term trading due to its amplified volatility.